NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Antiplatelet Medications and Brain Bleed Outcomes
TL;DR
This research reveals that patients on multiple or stronger antiplatelet medications face higher mortality after brain bleeds, offering clinicians a critical edge in treatment decisions and risk assessment.
Analysis of 426,481 patients over a decade found that stronger antiplatelet medications or dual therapy increased in-hospital mortality after brain bleeds, while aspirin alone did not.
These findings could guide better hospital care for brain bleed patients on antiplatelet medications, potentially saving lives and improving recovery outcomes for thousands annually.
A surprising study shows aspirin alone doesn't increase brain bleed death risk, but stronger antiplatelet medications do, challenging assumptions about these common heart medications.
Found this article helpful?
Share it with your network and spread the knowledge!
The analysis found that people hospitalized for a brain bleed who were taking multiple antiplatelet medications or medications stronger than aspirin before the bleed were more likely to die in the hospital compared to those not taking any antiplatelet medications.
People who were taking only aspirin before the brain bleed had the same risk of death as those not taking any antiplatelet medications, unlike those taking multiple antiplatelets or stronger medications.
This study distinguishes between different types of antiplatelet medications rather than grouping them all together, opening the door to research on how to improve care for brain bleed patients who have been taking these medications.
Researchers analyzed a decade of data for more than 400,000 adults in the U.S. hospitalized for a brain bleed (intracranial hemorrhage) from the American Heart Association's Get With The Guidelines-Stroke Registry.
The study was led by Dr. Santosh Murthy from Weill Cornell Medicine and will be presented at the American Stroke Association's International Stroke Conference 2026 in New Orleans.
The study included adults hospitalized for a brain bleed without traumatic brain injury or other types of stroke, excluding those on anticoagulant medication.
Among 426,481 people hospitalized with intracranial hemorrhage, 109,512 were taking only one antiplatelet, 17,009 were taking two antiplatelet medications, and 300,558 did not receive any antiplatelet treatment.
This is a preliminary research abstract presented at a scientific meeting; the findings are considered preliminary until published as full manuscripts in a peer-reviewed scientific journal.
Antiplatelet medications stop blood clot formation by making blood platelets less sticky, and are often prescribed to treat and prevent heart attacks and ischemic strokes.
The content mentions clopidogrel, prasugrel, and ticagrelor as examples of stronger antiplatelet medications that might be prescribed in addition to aspirin after a heart attack or ischemic stroke.
Curated from NewMediaWire
